

Consommation
et Corporations Canada
Bureau des brevets
Ottawa, Canada
K1A 0C9

Consumer and
Corporate Affairs Canada
Patent Office

(21) (A1) 2,061,538
(22) 1992/02/19
(43) 1993/08/20

5,036,7/24

⁵
(51) INTL.CL. C07D-215/14; C07D-215/16; C07D-401/12; C07D-405/12;
C07D-409/12; A61K-031/47; A61K-031/495

(19) (CA) APPLICATION FOR CANADIAN PATENT (12)

(54) 2-Substituted Quinolines, Processes for Their
Preparation and Their Use in Medicaments

(72) Raddatz, Siegfried - Germany (Federal Republic of) ;
Mohrs, Klaus-Helmut - Germany (Federal Republic of) ;
Matzke, Michael - Germany (Federal Republic of) ;
Fruchtmann, Romanis - Germany (Federal Republic of) ;
Hatzelmann, Armin - Germany (Federal Republic of) ;
Kohlsdorfer, Christian - Germany (Federal Republic of) ;
Mueller-Peddinghaus, Reiner - Germany (Federal Republic
of) ;
Theisen-Popp, Pia - Germany (Federal Republic of) ;

(73) Bayer Aktiengesellschaft - Germany (Federal Republic of)
;

(57) 14 Claims

Notice: The specification contained herein as filed

Canada


CCA 3254 (10-89) 41

2061538

23189-7312

ABSTRACT OF THE DISCLOSURE

Disclosed are novel 2-substituted quinolines of the formula:




(wherein A, B, D, E, G and L are each H, OH, halogen, cyano, carboxyl, nitro, CF_3 , OCF_3 , C_{1-8} alkyl, C_{1-8} alkoxy or optionally substituted C_{6-10} aryl, R^1 is halogen, cyano, nitro, azido, CF_3 , OCF_3 , SCF_3 , C_{1-8} alkoxy, C_{1-8} acyl, optionally substituted C_{1-8} alkyl, C_{6-10} aryl, C_{2-6} alkenyl, $-\text{NR}^4\text{R}^5$ [in which R^4 and R^5 are each H, C_{1-8} alkyl, phenyl, acetyl or benzoyl] or 5- or 6-membered heterocyclic ring, R^2 is C_{3-12} cycloalkyl or -alkenyl, R^3 is OR^6 or $-\text{NR}^7\text{SO}_2\text{R}^8$, R^6 is H, C_{1-8} alkyl or phenyl, R^7 is H or C_{1-6} alkyl, and R^8 is optionally substituted C_{6-10} aryl, C_{1-8} alkyl). The new substituted quinolines are useful as active substances in medicaments, in particular as lipoxygenase inhibitors.

The present invention relates to 2-substituted quinolines, processes for their preparation and their use in medicaments.

5 Substituted 4-(quinolin-2-yl-methoxy)phenylacetic acid derivatives and α -substituted 4-(quinolin-2-yl-methoxy)-phenylacetic acid derivatives have been disclosed in EP 344,519 (US 4,970,215) and EP 339,416.

The present invention now relates to 2-substituted quinolines of the general formula (I)

10



in which

15

A, B, D, E, G and L are identical or different and represent hydrogen, hydroxyl, halogen, cyano, carboxyl, nitro, trifluoromethyl, trifluoromethoxy or straight-chain or branched alkyl or alkoxy each having up to 8 carbon atoms, or represent aryl having 6 to 10 carbon atoms, which is

optionally substituted by halogen, hydroxyl, nitro or cyano,

15 R¹ represents halogen, cyano, nitro, azido, trifluoromethyl, trifluoromethoxy or trifluoromethylthio, or
5 represents straight-chain or branched alkoxy or acyl each having up to 8 carbon atoms, or
represents straight-chain or branched alkyl having up to 8 carbon atoms, which is optionally substituted by hydroxyl or alkoxy having up to 6 carbon atoms, or
10 represents aryl having 6 to 10 carbon atoms, or
represents straight-chain or branched alkenyl having up to 6 carbon atoms, or
represents a group of the formula -NR⁴R⁵,

15 in which

20 R⁴ and R⁵ are identical or different and denote hydrogen, straight-chain or branched alkyl having up to 8 carbon atoms, phenyl, acetyl or benzoyl, or
represents a saturated or unsaturated, optionally substituted 5- or 6-membered heterocycle having up to 3 hetero atoms from the series comprising sulphur, oxygen and nitrogen,

25 R² represents cycloalkyl or -alkenyl having 3 to 12 carbon atoms,

R³ represents a radical of the formula -OR⁶ or -NR⁷-SO₂-R⁸,

in which

5 R⁶ denotes hydrogen, straight-chain or branched alkyl having up to 8 carbon atoms, or phenyl,

R⁷ denotes hydrogen or straight-chain or branched alkyl having up to 6 carbon atoms,

10 R⁸ denotes aryl having 6 to 10 carbon atoms, which is optionally mono- or disubstituted by identical or different substituents from the series comprising halogen, cyano, hydroxyl, nitro, trifluoromethyl, trifluoromethoxy, trifluoromethylthio, or by straight-chain or branched alkyl or alkoxy each having up to 8 carbon atoms, or

15 denotes straight-chain or branched alkyl having up to 8 carbon atoms, which is optionally substituted by phenyl, which in turn can be substituted by halogen, cyano, nitro, trifluoromethyl, trifluoromethoxy, trifluoromethylthio or hydroxyl, or by straight-chain or branched alkyl or alkoxy each having up to 6 carbon atoms

and their physiologically acceptable salts.

5- and 6-membered heterocycles which are mentioned as preferred are those having up to 2 nitrogen atoms such as, for example, pyrryl, pyrazolyl, pyridyl, pyrimidyl, pyrazinyl or pyridazinyl, or furyl or thieryl.

5 In the context of the present invention, physiologically acceptable salts are preferred. Physiologically acceptable salts of the 2-substituted quinolines may be salts of the substances according to the invention with mineral acids, carboxylic acids or sulphonic acids. Particularly preferred salts are, for example, those with hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methanesulphonic acid, ethanesulphonic acid, toluenesulphonic acid, benzenesulphonic acid, naphthalenedisulphonic acid, acetic acid, propionic acid, lactic acid, tartaric acid, citric acid, fumaric acid, maleic acid or benzoic acid.

10 15 20 Salts in the context of the present invention are moreover salts of the monovalent metals such as alkali metals and the ammonium salts. Sodium salts, potassium salts and ammonium salts are preferred.

25 The compounds according to the invention exist in stereoisomeric forms which behave either as image and mirror image (enantiomers), or which do not behave as image and mirror image (diastereomers). The invention relates both to the antipodes and to the racemic forms as well as the diastereomer mixtures. The racemic forms, like the diastereomers, can be separated into the

stereoisomerically uniform constituents in a known manner [cf. E.L. Eliel, Stereochemistry of Carbon Compounds, McGraw Hill, 1962].

Preferred compounds of the general formula (I) are those

5 in which

A, B, D, E, G and L are identical or different and represent hydrogen, hydroxyl, fluorine, chlorine, bromine, carboxyl, nitro, trifluoromethyl, trifluoromethoxy or

10 represent straight-chain or branched alkyl or alkoxy each having up to 6 carbon atoms, or represent phenyl which is optionally substituted by fluorine, chlorine, bromine, hydroxyl, nitro or cyano,

15 R¹ represents fluorine, chlorine, bromine, iodine, cyano, nitro, azido, trifluoromethyl, trifluoromethoxy, or represents straight-chain or branched alkoxy or acyl each having up to 6 carbon atoms, or

20 represents straight-chain or branched alkyl having up to 6 carbon atoms, which is optionally substituted by hydroxyl or alkoxy having up to 4 carbon atoms, or represents straight-chain or branched alkenyl having up to 4 carbon atoms, or

25 represents a group of the formula -NR⁴R⁵,

in which

R⁴ and R⁵ are identical or different and denote hydrogen or straight-chain or branched alkyl having up to 4 carbon atoms,

5 or represent pyrryl, pyridyl, furyl or phenyl,

R² represents cycloalkyl having 3 to 12 carbon atoms,

R³ represents a radical of the formula -OR⁶ or -NR⁷-SO₂-R⁸,

in which

10 R⁸ denotes hydrogen or straight-chain or branched alkyl having up to 6 carbon atoms,

R⁷ denotes hydrogen or straight-chain or branched alkyl having up to 4 carbon atoms,

15 R⁹ denotes phenyl which is optionally substituted by fluorine, chlorine, bromine, iodine, cyano or by straight-chain or branched alkyl or alkoxy each having up to 6 carbon atoms, or denotes straight-chain or branched alkyl having up to 6 carbon atoms, which is optionally substituted by phenyl which can in turn be substituted by fluorine, chlorine, bromine or trifluoromethyl or by straight-chain or

20

branched alkyl or alkoxy each having up to
4 carbon atoms

and their physiologically acceptable salts.

5 Particularly preferred compounds of the general formula
(I) are those

in which

10 A, B, D, E, G and L are identical or different and
represent hydrogen, hydroxyl, fluorine, chlorine,
bromine or straight-chain or branched alkyl having
up to 4 carbon atoms,

15 R¹ represents fluorine, chlorine, bromine, nitro, azido
or trifluoromethoxy, or
represents straight-chain or branched alkoxy or acyl
each having up to 4 carbon atoms, or
represents straight-chain or branched alkyl having
up to 4 carbon atoms, which is optionally substi-
tuted by hydroxyl or methoxy, or
represents straight-chain or branched alkenyl having
up to 4 carbon atoms, or
20 represents a group of the formula -NR⁴R⁵,

in which

R⁴ and R⁵ are identical or different and
denote hydrogen or straight-chain or branched
alkyl having up to 3 carbon atoms,

or represents pyrryl, furyl or phenyl,

R² represents cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl,

5 R³ represents a radical of the formula -OR⁶ or -NR⁷-SO₂-R⁸,

in which

R⁶ denotes hydrogen or straight-chain or branched alkyl having up to 4 carbon atoms,

R⁷ denotes hydrogen, methyl or ethyl,

10 R⁸ denotes phenyl which is optionally substituted by methyl, fluorine, chlorine, bromine, iodine, methoxy or trifluoromethyl, or denotes straight-chain or branched alkyl having up to 4 carbon atoms, which is optionally substituted by phenyl which can in turn be substituted by fluorine, chlorine, bromine, methyl or methoxy


15 and their physiologically acceptable salts.

20 Very particularly preferred compounds of the formula (I) are those in which A, B, D, E, G and L represent hydrogen. Those compounds are also very particularly preferred in which the radical -CHR²-COR³ is in the 4-position

relative to the quinolylmethoxy radical.

Processes for the preparation of the compounds of the general formula (I) according to the invention have additionally been found, characterised in that

5 [A] in the case where R³ represents the group -OR⁶
 [A₁] either compounds of the general formula (IIa)



in which


R¹ and R² have the abovementioned meaning,

10 W represents a hydroxyl protective group such as benzyl or tert.-butyl,

and

R⁶ has the abovementioned meaning of R⁶ but does not represent hydrogen,

15 are converted, after elimination of the protective group, by etherification with 2-halogenomethylquinolines of the general formula (III)



(III)


in which

A, B, D, E, G and L have the abovementioned meaning

and

5 Y represents halogen, in particular chlorine or bromine,

in inert solvents into the compounds of the general formula (IVa)




10 in which

A, B, D, E, G, L, R¹, R² and R⁶ have the abovementioned meaning,

and the latter in the case of the esters (R⁶ ≠ H) are then hydrolysed,

5 or


[A₂] compounds of the general formula (IIb)



in which

R¹ and R⁶ have the abovementioned meaning,

10 are converted, after elimination of the protective group, initially by etherification with 2-halogenomethyl-quinolines of the general formula (III) in inert solvents into compounds of the general formula (IVb)



in which

A, B, D, E, G, L, R¹ and R⁶ have the abovementioned meaning,

5 and the latter are then alkylated with compounds of the general formula (V)



in which

R² has the abovementioned meaning


and

10 Z represents chlorine, bromine or iodine,

in inert solvents and in the case of the esters (R⁶ ≠ H) the esters are hydrolysed

or


15 [B] in the case where R³ represents the group -NR⁷-SO₂R⁸, compounds of the general formula (IVc)



in which

A, B, D, E, G, L, R¹ and R² have the abovementioned meaning,

5 are amidated in inert solvents, if appropriate in the presence of a base, with sulphonamides of the general formula (VI)



in which


10 R⁷ and R⁸ have the abovementioned meaning,
and

15 [C] in the case of the enantiomers the corresponding enantiomerically pure acids (IVc) are separated by a customary method and reacted further by the abovementioned processes, it being possible for the substituent R¹ to be varied in any of the abovementioned steps, optionally by customary chemical methods.


The processes according to the invention can be illustrated by way of example by the following reaction scheme:

[A2]






[A1]



[B]



The elimination of the protective groups from the corresponding ethers (IIa) and (IIb) is carried out by a customary method, for example by hydrogenolytic cleavage of the benzyl ether in the abovementioned inert solvents in the presence of a catalyst with hydrogen gas [cf. additionally Th. Green: "Protective Groups in Organic Synthesis", J. Wiley & Sons, 1981, New York].

The etherification can be carried out in inert solvents, optionally in the presence of a base. Solvents for the etherification can be inert organic solvents which do not change under the reaction conditions. These preferably include ethers such as, for example, dioxane, tetrahydrofuran or diethyl ether, halogenohydrocarbons such as dichloromethane, trichloromethane, tetrachloromethane, 1,2-dichloroethane or trichloroethylene, hydrocarbons such as benzene, xylene, toluene, hexane, cyclohexane or petroleum fractions, nitromethane, dimethylformamide, acetonitrile, acetone or hexamethylphosphoric triamide. It is also possible to employ mixtures of these solvents.

Bases which can be employed for the etherification are inorganic or organic bases. These preferably include alkali metal hydroxides such as, for example, sodium hydroxide or potassium hydroxide, alkaline earth metal hydroxides such as, for example, barium hydroxide, alkali metal carbonates such as sodium carbonate or potassium carbonate, alkaline earth metal carbonates such as calcium carbonate, or organic amines (trialkyl(C₁-C₆)-amines) such as triethylamine, or heterocycles such as

pyridine, methylpiperidine, piperidine or morpholine.

It is also possible to employ alkali metals such as sodium and its hydrides, such as sodium hydride, as bases.

5 The etherification is in general carried out in a temperature range from 0°C to +150°C, preferably from +10°C to +100°C.

10 The etherification is in general carried out at normal pressure. However, it is also possible to carry out the process at reduced pressure or elevated pressure (for example in a range from 0.5 to 5 bar).

15 In general, 0.5 to 5 mol, preferably 1 to 2 mol, of halide (III) are employed relative to 1 mol of the reaction component. The base is in general employed in an amount of 0.5 to 5 mol, preferably of 1 to 3 mol, relative to the halide.

The compounds of the general formula (IIa) and (IIb) are known per se or can be prepared by a customary method [cf. J. Org. Chem. 31, 2658 (1966)].

20 The compounds of the general formula (III) and their preparation are also known [cf. Chem. Ber. 120, 649 (1987)].

Suitable solvents for the process according to the

invention and for the alkylation are customary organic solvents which do not change under the reaction conditions. These preferably include ethers such as diethyl ether, dioxane, tetrahydrofuran, glycol dimethyl ether, or hydrocarbons such as benzene, toluene, xylene, hexane, cyclohexane or petroleum fractions, or halogenohydrocarbons such as dichloromethane, trichloromethane, tetrachloromethane, dichloroethylene, trichloroethylene or chlorobenzene, or ethyl acetate, or triethylamine, pyridine, dimethyl sulphoxide, dimethylformamide, hexamethylphosphoric triamide, acetonitrile, acetone or nitromethane. It is also possible to use mixtures of the solvents mentioned. Dichloromethane is preferred.

The alkylation is carried out in the abovementioned solvents at temperatures from 0°C to +150°C, preferably at room temperature to 100°C, and at normal pressure.

The amidation is in general carried out in inert solvents in the presence of a base and of a dehydrating agent.

Suitable solvents here are inert organic solvents which do not change under the reaction conditions. These include halogenohydrocarbons such as dichloromethane, trichloromethane, tetrachloromethane, 1,2-dichloroethane, trichloroethane, tetrachloroethane, 1,2-dichloroethylene or trichloroethylene, hydrocarbons such as benzene, xylene, toluene, hexane, cyclohexane or petroleum fractions, nitromethane, dimethylformamide, acetonitrile or hexamethylphosphoric triamide. It is also possible to

employ mixtures of the solvents mentioned. Dichloro-methane is particularly preferred.

5 Suitable bases for the amidation are the customary basic compounds. These preferably include alkali metal hydroxides and alkaline earth metal hydroxides such as lithium hydroxide, sodium hydroxide, potassium hydroxide or barium hydroxide, alkali metal hydrides such as sodium hydride, alkali metal carbonates or alkaline earth metal carbonates such as sodium carbonate, potassium carbonate, or alkali metal alkoxides such as, for example, sodium methoxide or ethoxide, potassium methoxide or ethoxide or potassium tert.-butoxide, or organic amines such as benzyltrimethylammonium hydroxide, tetrabutylammonium hydroxide, pyridine, triethylamine or N-methylpiperidine.

10

15 The amidation is in general carried out in a temperature range from 0°C to 150°C, preferably at 25°C to 40°C.

20 The amidation is in general carried out at normal pressure. However, it is also possible to carry out the process at reduced pressure or at elevated pressure (for example in a range from 0.5 to 5 bar).

25 When carrying out the amidation, the base is in general employed in an amount of 1 to 3 mol, preferably of 1 to 1.5 mol, relative to 1 mol of the carboxylic acid (VIc).

Suitable dehydrating reagents are carbodiimides such as, for example, diisopropylcarbodiimide,

5 dicyclohexyl-carbodiimide or N-(3-dimethylaminopropyl)-
N'-ethylcarbodiimide hydrochloride or carbonyl compounds
such as carbonyldimidazole or 1,2-oxazolium compounds
such as 2-ethyl-5-phenyl-1,2-oxazolium-3-sulphonate or
10 propanephosphonic anhydride or isobutyl chloroformate or
benzotriazolyloxy-tris-(dimethylamino)phosphonium
hexafluorophosphate or diphenyl aminophosphonate or
methanesulphonyl chloride, optionally in the presence of
bases such as triethylamine or N-ethylmorpholine or
N-methylpiperidine or dicyclohexylcarbodiimide and N-
hydroxysuccinimide [cf. J.C. Sheehan, S.L. LEdis, J. Am.
Chem. Soc. 95, 875 (1973); F.E. Freeman et al., J. Biol.
Chem. 225, 507 (1982) and N.B. Beneton, K. Kluroda, Int.
Pept. Prot. Res. 13, 403 (1979), 17, 187 (1981)].

15 The compounds of the general formulae (IVa), (IVb) and
(IVc) are new and can be prepared by the abovementioned
method.

20 The compounds of the general formula (V) are known [cf.
Beilstein 5,19/5,24/5,29] or can be prepared from the
corresponding alcohols or cycloalkenes by customary
methods.

25 The compounds of the general formula (VI) are known [cf.,
for example, Beilstein 11/104].

The phenyl-substituted quinolines according to the
invention can be employed as active substances in medica-
ments. The substances can act as inhibitors of enzymatic

reactions in the context of arachidonic acid metabolism, in particular lipoxygenase.

They are thus preferred for the treatment and prevention of diseases of the respiratory tract such as allergies/asthma, bronchitis, emphysema, shock lung, pulmonary hypertension, inflammations/rheumatism and oedemas, thromboses and thromboembolisms, ischaemias (peripheral, cardiac, cerebral circulatory disorders), cardiac and cerebral infarcts, angina pectoris, arteriosclerosis, in tissue transplantation, dermatoses such as psoriasis, inflammatory dermatoses and for cytoprotection in the gastrointestinal tract.

The phenyl-substituted quinolines according to the invention can be used both in human medicine and in veterinary medicine.

The pharmacological effects of the substances according to the invention are determined by the following method:

As a measure of lipoxygenase inhibition, the release of leukotriene B₄ (LTB₄) in polymorphonuclear human leukocytes (PMN) was determined after addition of substances and Ca ionophore by means of reverse phase HPLC according to Borgeat, P. et. al., Proc. Nat. Acad. Sci. 76, 2148-2152 (1979).

The values obtained by this test for some compounds according to the invention are shown in Table 1 by way of

example:

Table 1:

<u>Example No.</u>	<u>5-LO IC₅₀ (μmol/l)</u>
5 1	2.50
27	0.69
40	0.79
41	0.56

10 The present invention also includes pharmaceutical preparations which, in addition to inert, non-toxic, pharmaceutically suitable auxiliaries and excipients, contain one or more compounds of the general formula (I) or which consist of one or more active substances of the formula (I), and processes for the production of these preparations.

15 The active substances of the formula (I) should be present in these preparations in a concentration of 0.1 to 99.5 % by weight, preferably of 0.5 to 95 % by weight of the total mixture.

20 In addition to the active substances of the formula (I), the pharmaceutical preparations can also contain other pharmaceutical active substances.

The abovementioned pharmaceutical preparations can be prepared in a customary manner by known methods, for example with the auxiliary(ies) or excipient(s).


5 In general it has proved advantageous to administer the active substance(s) of the formula (I) in total amounts of about 0.01 to about 100 mg/kg, preferably in total amounts of about 1 mg/kg to 50 mg/kg of body weight every 24 hours, if appropriate in the form of several individual doses, to achieve the desired results.

10 However, it may be advantageous to deviate from the amounts mentioned, in particular depending on the type and the body weight of the subject to be treated, on individual behaviour towards the medicament, the nature and severity of the disease, the type of preparation and administration, and the time or interval at which administration takes place.

Starting Compounds

15 Example I

Methyl 3-fluoro-5-hydroxyphenylacetate




20 19.8 g (0.116 mol) of 3-fluoro-4-hydroxyphenylacetic acid are dissolved in 100 ml of methanol, 1 ml of conc. sulphuric acid is added and the mixture is heated to

boiling for 2 h. After cooling, the solvent is evaporated in vacuo, the residue is taken up in 250 ml of dichloromethane and the solution is extracted twice with saturated NaHCO₃ solution. After drying, the organic phase is evaporated to dryness in vacuo and a viscous amber-coloured oil is obtained.


5 Yield: 18.4 g (85.8 % of theory)

The examples shown in Table I are prepared in analogy to the procedure of Example I:

10 Table I:



	Ex. No.	W	R ¹	R ²	m.p. °C	Yield (%)
15	II	H	Br	H	oil	82.0
	III	H	NO ₂	H	147	quantitative


Example IV**Methyl 2-(4-methallyloxyphenyl)-2-cyclopentyl-acetate**

5 10 g (0.043 mol) of methyl 2-(4-hydroxyphenyl)-2-cyclo-
penty1-acetate are dissolved in 200 ml of dimethyl-
formamide and 4.1 g (0.043 mol) of methallyl chloride and
5.9 (0.043 mol) of potassium carbonate are added with
stirring. The mixture is allowed to react overnight at
100°C. After cooling, the solvent is evaporated in vacuo,
10 the residue is taken up in 200 ml of dichloromethane, the
solution is washed twice with 100 ml of water, the
organic phase is dried using sodium sulphate and the
product from evaporation in vacuo is purified by column
15 chromatography (silica gel 60, eluent: toluene/ethyl
acetate = 100:5).

Yield: 7.66 g (61.9 % of theory) of pale yellow oil

Example V

Methyl 2-(4-hydroxy-3-methallylphenyl)-2-cyclopentylacetate




5 7.6 g (0.026 mol) of the compound from Example IV are dissolved in 50 ml of freshly distilled diethylaniline and the mixture is heated overnight at 200°C (Claisen rearrangement). After cooling, the solvent is distilled off in *vacuo*, the residue is taken up in 200 ml of dichloromethane and the solution is washed twice with 40 ml of 2N hydrochloric acid in order to extract residues of diethylaniline. It is then washed until neutral, dried with sodium sulphate and concentrated to a small volume. Purification is carried out by column chromatography (silica gel 60, eluent: toluene/ethyl acetate = 9:1).

10 Yield: 4.3 g (57.4 % of theory) of pale yellow oil.

15

Example VI

Methyl 2-(4-hydroxy-3-isobutylphenyl)-2-cyclopentylacetate




5 4 g (0.014 mol) of the compound from Example V are dissolved in 30 ml of methanol and 10 ml of acetic acid and hydrogenated at 5.3 bar using Pd/C as a catalyst. Reaction time: 2.5 h. After filtering off the catalyst, the solvent is evaporated in vacuo and a slightly yellowish oil is obtained.

10 Yield: 3.6 g (88.7 % of theory)

Example VII


Methyl 4-acetoxy-phenylacetate



10 g (0.06 mol) of methyl 4-hydroxyphenylacetate are treated with 18.36 g (0.18 mol) of acetic anhydride (17 ml) and 1 ml of pyridine and the mixture is heated to boiling for 2 hours. The solvents are largely evaporated in vacuo, the residue is taken up in water and the solution is extracted with ethyl acetate. After drying using sodium sulphate, the solvent is distilled off in vacuo and a pale yellow, thin oil is obtained.
 5 Yield: 12.3 g (98.6 % of theory)

10 Example VIII


Methyl 4-hydroxy-3-acetyl-phenylacetate



15 5.3 g of aluminium chloride are introduced under argon, 4 g (0.019 mol) of the compound from Example VII are added and the mixture is heated at 150°C for 2 hours (Fries rearrangement). After cooling, 50 ml of dichloromethane are added, and the mixture is heated briefly to boiling and filtered. Purification is carried out by column chromatography (silica gel 60, eluent: toluene/ethyl acetate = 8:2).
 20 Yield: 2.4 g (50.7 % of theory) of yellow oil.

The examples shown in Table II are prepared in analogy to the procedure of Example VII:


Table II:



5	Ex. No.	R ¹	R ²	m.p. °C	Yield (%)
	IX	H ₃ C-CO-	H	oil	86.8
	X	H	H ₃ C-CO-	oil	96.0

Example XI

10 Methyl 2-(4-hydroxy-3-nitrophenyl)-2-cyclopentyl-acetate




15 22.9 g (0.1 mol) of methyl 2-(4-hydroxyphenyl)-2-cyclopentyl-acetate are dissolved in 50 ml of CH₂Cl₂ and added dropwise at 5°C to a solution of 50 ml of conc. HNO₃/50 ml of H₂O. The mixture is stirred for 15 min, then

100 ml of H₂O are added and the organic phase is separated off. The aqueous phase is extracted three times with 50 ml of CH₂Cl₂, and the organic phases are washed 5 times with water, dried, concentrated to a small volume and filtered through silica gel. After concentration, the product is obtained in 71 % yield (20 g). The product is further processed in crude form.

5

Example XII

Methyl 2-(3-amino-4-hydroxy-phenyl)-2-cyclopentyl-acetate




10 5.6 g (20 mmol) of the compound from Example XI are hydrogenated at 4 atm. in 100 ml of ethanol with the addition of 0.5 g of palladium/carbon (10 % strength). The catalyst is filtered off with suction, the filtrate is concentrated and the residue is further reacted without further purification (quantitative yield).

15

Example XIII

Methyl 2-(3-azido-4-hydroxy-phenyl)-2-cyclopentyl-acetate




5 5.0 g (20 mmol) of the crude product from Example XII are dissolved in 20 ml of H₂O, 10 ml of ethanol and 20 ml of conc. HCl and the solution is diazotised at 0°C with 1.8 g (26 mmol) of sodium nitrite in 10 ml of H₂O. After evolution of N₂ has ended, the mixture is extracted three times with 100 ml of CH₂Cl₂, the organic phases are concentrated and the residue is chromatographed on silica gel 60 (CH₂Cl₂/MeOH = 100:2).

10 Yield: 4.5 g (82 % of theory)
M.p.: 59-60°C

Example XIV

15 Methyl 2-[3-fluoro-4-(quinolin-2-yl-methoxy)phenyl]-acetate



18.4 g (0.1 mol) of the compound from Example I are

5 dissolved in 50 ml of DMF and 4 g (0.1 mol) of NaOH in 40 ml of methanol are added. 17.8 g (0.1 mol) of 2-chloromethylquinoline in 50 ml of DMF are added dropwise to this mixture with stirring and it is then heated at 100°C for 5 h. After cooling, the solvent is evaporated in vacuo, the residue is taken up in dichloromethane, and the solution is washed twice with water, dried and concentrated in vacuo to a small volume.


10 Separation is carried out by column chromatography (silica gel 60, eluent: toluene/ethyl acetate = 9:1 to 8:2).

Yield: 28 g (86 % of theory) of yellow oil.

Example XV

2-[3-Fluoro-4-(quinolin-2-yl-methoxy)phenyl]-acetic acid

15



20

25 g (0.077 mol) of the compound from Example XIV are dissolved in 300 ml of methanol and 125 ml of 1 molar sodium hydroxide solution are added. The mixture is stirred at the boiling point for 3 h, allowed to cool and neutralised with 1N hydrochloric acid. The whole is evaporated to dryness in vacuo, and covered with 50 ml of


water and with 150 ml of dichloromethane. The dichloromethane phase is dried and the solvent is evaporated in vacuo. Colourless crystals remain.

Yield: 19.5 g (81.5 % of theory)

5 M.p.: 177-179°C

Example XVI

2-[3-Fluoro-4-(quinolin-2-yl-methoxy)phenyl]-acetyl-methanesulphonamide




10 6 g (0.019 mol) of the compound from Example XV, 1.9 g (0.019 mol) of dried methanesulphonamide, 3.8 g (0.019 mol) of N-ethyl-N'-dimethylaminopropylcarbodiimide hydrochloride and 2.4 g (0.019 mol) of dimethylamino-pyridine are dissolved in 40 ml of dichloromethane and the mixture is stirred at room temperature for 60 h. It is then evaporated to dryness in vacuo, the residue is taken up in 40 ml of dichloromethane and the solution is washed twice with 20 ml of water. After drying the organic phase using Na_2SO_4 , it is evaporated in vacuo and the residue is separated by column chromatography (silica gel 60, eluent dichloromethane/ethyl acetate/glacial

acetic acid = 10:1:1).

Yield: 5.2 g (70.5 % of theory) of colourless crystals
M.p.: 171°C

Example XVII

5 2-[3-Fluoro-4-(quinolin-2-yl-methoxy)phenyl]-acetyl-benzylsulphonamide




10

In analogy to Example XVI, the title compound is obtained from 4 g (0.013 mol) of the compound from Example XV, 2.22 g (0.013 mol) of dried benzylsulphonamide, 2.49 g (0.013 mol) of N-ethyl-N'-dimethylaminopropyl-carbodi-imide hydrochloride and 1.59 g (0.013 mol) of dimethyl-aminopyridine.

Yield: 4.4 g (72.9 % of theory) of colourless crystals
M.p.: 156°C

Example XVIII

Methyl 2-[3-chloro-4-(quinolin-2-yl-methoxy)phenyl]-acetate




5 The title compound is prepared in analogy to the procedure of Example XIV from 5.3 g (0.03 mol) of 2-chloromethylquinoline, 6 g (0.03 mol) of methyl 3-chloro-4-hydroxyphenylacetate and 1.2 g (0.03 mol) of sodium hydroxide.

10 Yield: 8.7 g (84.9 % of theory) of colourless crystals
M.p.: 79°C

Example XIX

2-[3-Chloro-4-(quinolin-2-yl-methoxy)phenyl]-acetic acid




In analogy to the procedure of Example XV, the title compound is obtained from 4 g (0.012 mol) of the compound from Example XVIII and 18 ml of 1N sodium hydroxide solution.

5 Yield: 3.5 g (89.1 % of theory) of colourless crystals
M.p.: 203-205°C

Example XX


Methyl 2-[3-bromo-4-(quinolin-2-yl-methoxy)phenyl]acetate



10 In analogy to the procedure of Example XIV, the title compound is prepared from 17 g (0.07 mol) of the compound from Example II, 12.32 g (0.07 mol) of 2-chloromethyl-quinoline and 2.8 g (0.07 mol) of sodium hydroxide.
Yield: 23.2 g (85.8 % of theory) of slightly yellowish
15 crystals
M.p.: 90°C

Example XXI

2-[3-Bromo-4-(quinolin-2-yl-methoxy)phenyl]acetic acid




5 In analogy to the procedure of Example XV, the title compound is prepared from 3 g (7.77 mmol) of the compound from Example XX and 12 ml of 1N sodium hydroxide solution (12 mmol).

Yield: 2.5 g (86.5 % of theory) of colourless crystals
M.p.: 206-208°C (dec.)

10 Example XXII

2-[3-Bromo-4-(quinolin-2-yl-methoxy)phenyl]acetyl-methanesulphonamide




In analogy to the procedure of Example XVI, the title

compound is prepared from 2.8 g (7.5 mmol) of the compound from Example XXI, 0.71 g (7.5 mmol) of dried methanesulphonamide, 1.44 g (7.5 mmol) of N-ethyl-N'-dimethylaminopropylcarbodiimide hydrochloride and 0.92 g (7.5 mmol) of dimethylaminopyridine.

5 Yield: 0.86 g (25.5 % of theory) of colourless crystals
M.p.: 212°C (dec.)

Example XXIII

10 Methyl 2-[3-methoxy-4-(quinolin-2-yl-methoxy)phenyl]-acetate




15 In analogy to the procedure of Example XIV, the title compound is prepared from 16 g (0.082 mol) of methyl 3-methoxy-4-hydroxyphenylacetate, 14.5 g (0.082 mol) of 2-chloromethylquinoline and 3.28 g (0.082 mol) of sodium hydroxide.

Yield: 20.5 g (74.1 % of theory) of colourless crystals
M.p.: 69°C

Example XXIV

2-[3-Methoxy-4-(quinolin-2-yl-methoxy)phenyl]-acetic acid




5 The title compound is prepared from 3 g (8.9 mmol) of the compound from Example XXIII and 12 ml of 1N sodium hydroxide solution analogously to the procedure of Example XV.

Yield: 2.4 g (83.4 % of theory) of colourless crystals
M.p.: 168-170°C (dec.)

10 Example XXV

Ethyl 2-[3-trifluoromethylthio-4-(quinolin-2-yl-methoxy)-phenyl]acetate




In analogy to the procedure of Example XIV, the title compound is prepared from 10 g (0.036 mol) of ethyl 4-hydroxy-3-trifluoromethylthiophenylacetate, 7.7 g (0.036 mol) of 2-chloromethylquinoline and 2.88 g (0.072 mol) of sodium hydroxide.

5 Yield: 7.55 g (49.8 % of theory) of yellow oil.

Example XXVI

2-[3-Trifluoromethylthio-4-(quinolin-2-yl-methoxy)-phenyl]acetic acid

10




15

In analogy to the procedure of Example XV, the title compound is prepared from 2.1 g (5 mmol) of the compound from Example XXV and 0.4 g (0.01 mol) of sodium hydroxide in dioxane/water.

Yield: 1.8 g (91.6 % of theory) of colourless crystals
M.p.: 152°C

Example XXVII


2-[3-Trifluoromethylthio-4-(quinolin-2-yl-methoxy)-phenyl]acetyl-methanesulphonamide



5 In analogy to the procedure of Example XV, the title compound is prepared from 1.2 g (3.1 mmol) of the compound from Example XXVI, 0.38 g (4 mmol) of methanesulphonamide, 0.77 g (4 mmol) of N-ethyl-N'-dimethylaminopropyl-carbodiimide hydrochloride and 0.49 g (4 mmol) of dimethylaminopyridine.
 Yield: 1.2 g (82.4 % of theory) of colourless crystals
 M.p.: 183°C (dec.)

10 Example XXVIII

Methyl 2-[3-nitro-4-(quinolin-2-yl-methoxy)phenyl]acetate



In analogy to the procedure of Example XIV, the title compound is prepared from 10.75 g (0.0509 mol) of the


compound from Example III, 10.9 g (0.051 mol) of 2-chloromethylquinoline and 4.32 g (0.11 mol) of sodium hydroxide.

Yield: 3.3 g (18.4 % of theory) of yellow crystals

5 M.p.: 177°C

Example XXIX

Methyl 2-[3-amino-4-(quinolin-2-yl-methoxy)phenyl]acetate




10 15 g (0.043 mol) of the compound from Example XXVIII are dissolved in 100 ml of tetrahydrofuran and 100 ml of methanol and 4 g (0.08 mol) of hydrazine monohydrate are added. Raney nickel is added in portions under argon with stirring, the temperature rising to 50°C. After the evolution of gas has ended, the mixture is heated to boiling for a further hour and then filtered while hot. The filtrate is concentrated in vacuo and the residual oil is taken up using 250 ml of dichloromethane. After washing twice using water and drying with sodium sulphate, the solvent is evaporated in vacuo and a colourless oil is obtained which crystallises overnight.

15 Yield: 12.5 g (90.3 % of theory) of colourless crystals

20 M.p.: 75°C

Example XXX

Methyl 2-[3-(1-pyrryl)-4-(quinolin-2-yl-methoxy)phenyl]-acetate




5 5 g (0.016 mmol) of the compound from Example XXIX are dissolved in 70 ml of acetic acid, 2.78 g (0.02 mol) of 2,5-dimethoxytetrahydrofuran are added and the mixture is heated to boiling for 2 hours. After distilling off the acetic acid in vacuo, taking up the residue in 200 ml of dichloromethane, extracting with water, drying with sodium sulphate and concentrating in vacuo to a small volume, the brown oil which remains (5 g) is separated by column chromatography (silica gel 60, eluent: toluene/ethyl acetate = 4:1).

10 Yield: 3.2 g (53.8 % of theory) of colourless crystals
M.p.: 102°C

Example XXXI

2-[3-(1-Pyrryl)-4-(quinolin-2-yl-methoxy)phenyl]acetic acid




In analogy to the procedure of Example XV, the title compound is prepared from 0.8 g (2 mmol) of the compound from Example XXX and 0.2 g (5 mmol) of sodium hydroxide in 50 ml of isopropanol.

5 Yield: 0.7 g (97.8 % of theory) of colourless crystals
M.p.: 173°C

Example XXXII

Methyl 2-[3-vinyl-4-(quinolin-2-yl-methoxy)phenyl]acetate




10 200 mg (0.21 mmol) of the catalyst $[\text{P}(\text{phenyl})_3]_2\text{Pd}$ are weighed into a 50 ml brown glass flask (flushed with argon) and 2 g (5.2 mmol) of the compound from Example XX and 1.4 ml (5.2 mmol) of $\text{Bu}_3\text{SnCH=CH}_2$ ($d = 1.086$), both

5 dissolved in 10 ml of toluene, are added under argon. The mixture is heated to boiling for 20 hours with stirring in a light-protected apparatus. The solvent is then evaporated in vacuo and the residue is separated by column chromatography (silica gel 60, eluent: toluene/ethyl acetate = 4:1).

Yield: 1.5 g (86.6 % of theory) of colourless crystals
M.p.: 69 °C

Example XXXIII

10 2-[3-Vinyl-4-(quinolin-2-yl-methoxy)phenyl]acetic acid




15 In analogy to the procedure of Example XV, the title compound is prepared from 1.1 g (3.3 mmol) of the compound from Example XXXII and 5 ml (5 mmol) of 1N sodium hydroxide solution.

Yield: 1.0 g (95.0 % of theory) of colourless crystals
M.p.: 173 °C

Example XXXIV

Methyl 2-[3-ethyl-4-(quinolin-2-yl-methoxy)phenyl]acetate

2061538



5


14.3 g (0.0429 mol) of the compound from Example XXXII are dissolved in 150 ml of methanol and 15 ml of glacial acetic acid, 1.5 g of 5 % strength Pd-C are added, and the reaction mixture is heated to 30-35°C and hydrogenated. It is filtered through silica gel, the filtrate is concentrated in vacuo and the residue is recrystallised from isopropanol.

Yield: 8.5 g (59.1 % of theory) of colourless crystals
M.p.: 72°C

10

Example XXXV

2-[3-Ethyl-4-(quinolin-2-yl-methoxy)phenyl]acetic acid




The title compound is prepared from 1.5 g (4.48 mmol) of the compound from Example XXXIV and 10 ml (10 mmol) of 1N

sodium hydroxide solution analogously to the procedure of Example V.

Yield: 1.4 g (97.4 % of theory) of colourless crystals
M.p.: 144 °C

5 Example XXXVI

N-[3-Ethyl-4-(quinolin-2-yl-methoxy)phenyl]acetyl methane-sulphonamide




10 Analogously to the procedure of Example XVI, the title compound is prepared from 1.7 g (5.3 mmol) of the compound from Example XXXV, 0.6 g (6 mmol) of methanesulphonamide, 1.2 g (6 mmol) of N-methyl-N'-dimethylaminopropylcarbodiimide hydrochloride and 0.8 g (6 mmol) of dimethylaminopyridine.

15 Yield: 1.4 g (66.3 % of theory) of colourless crystals
M.p.: 170 °C

Example XXXVII


Methyl 2-[3-allyl-4-(quinolin-2-yl-methoxy)phenyl]acetate



5 In analogy to the procedure of Example XXXII, the title compound is prepared from 16.6 g (0.043 mol) of the compound from Example XX, 13.6 g (0.043 mol) of $Bu_3-Sn-CH_2-CH=CH_2$ and 2.0 g (0.0017 mol) of $[P(phenyl)_3]_4Pd$.
 Yield: 7.6 g (50.9 % of theory) of colourless crystals
 M.p.: 71°C

Example XXXVIII

10 2-[3-Allyl-4-(quinolin-2-yl-methoxy)phenyl]acetic acid




In analogy to the procedure of Example XV, the title

compound is prepared from 2.0 g (5.8 mmol) of the compound from Example XXXVII and 10 ml (10 mmol) of 1N sodium hydroxide solution.

5 Yield: 1.7 g (88.0 % of theory) of colourless crystals
M.p.: 130 °C

Example XXXIX

Methyl 2-[3-propyl-4-(quinolin-2-yl-methoxy)phenyl]-acetate




10 In analogy to the procedure of Example XXXIV, the title compound is prepared from 7.5 g (0.0225 mol) of the compound from Example XXXVII and 0.8 g of Pd/C (5 %) using hydrogen.

Yield: 6.5 g (82.8 % of theory) of yellowish oil

15 Example XL

2-[3-Propyl-4-(quinolin-2-yl-methoxy)phenyl]acetic acid




In analogy to the procedure of Example XV, the title compound is prepared from 1.5 g (4.3 mmol) of the compound from Example XXXIX and 10 ml (10 mmol) of 1N sodium hydroxide solution.

5 Yield: 1.4 g (97.2 % of theory) of colourless crystals
M.p.: 135°C

Example XLI

2-[3-Propyl-4-(quinolin-2-yl-methoxy)phenyl]-acetyl-methanesulphonamide

10




In analogy to the procedure of Example XVI, the title compound is prepared from 1.7 g (5.1 mmol) of the

compound from Example XL, 0.6 g (6 mmol) of methanesulphonamide, 1.2 g (6 mmol) of N-ethyl-N'-dimethylamino-carbodiimide hydrochloride and 0.8 g (6 mmol) of dimethylaminopyridine.

5 Yield: 1.5 g (71.4 % of theory) of colourless crystals
M.p.: 155°C (dec.)

Example XLII

Methyl 2-[3-acetyl-4-(quinolin-2-yl-methoxy)-phenyl]acetate




10 In analogy to the procedure of Example XIV, the title compound is prepared from 2.9 g (0.014 mol) of the compound from Example VIII, 2.5 g (0.014 mol) of 2-chloromethylquinoline and 0.56 g (0.014 mol) of sodium hydroxide.

15 Yield: 2.1 g (43.0 % of theory) of colourless oil

Example XLIII

2-[3-Acetyl-4-(quinolin-2-yl-methoxy)phenyl]acetic acid




5 In analogy to the procedure of Example XV, the title compound is prepared from 1 g (2.9 mmol) of the compound from Example XLII and 0.13 g (5.8 mmol) of lithium hydroxide in 10 ml of water.

Yield: 0.7 g (72.1 % of theory) of colourless crystals
M.p.: 119 °C (dec.)

10 Preparation Examples (general formula I)Example 1

Methyl 2-[3-fluoro-4-(quinoline-2-methoxy)phenyl]-2-cyclopentylacetate




0.45 g (0.015 mol) of 80 % pure NaH is suspended in DMF under argon, and 5 g (0.015 mmol) of the compound from Example XIV in 80 ml of DMF are added to the mixture. After evolution of hydrogen has ended, the mixture is subsequently additionally stirred for 1 h. 2.4 g = 1.61 ml (0.015 mol) of cyclopentyl bromide in 100 ml of DMF are then added dropwise in the course of 1 h and the mixture is allowed to react further overnight. The solvent is evaporated to dryness in vacuo, the residue is taken up in dichloromethane, the solution is extracted with dilute hydrochloric acid and NaHCO₃ solution, dried and concentrated to a small volume, and the mixture is separated by column chromatography (silica gel 60, eluent: toluene/ethyl acetate = 9:1).

Yield: 3.5 g (59.3 % of theory) of colourless crystals
M.p.: 75 °C

Example 2

Methyl 2-[3-methoxy-4-(quinolin-2-yl-methoxy)phenyl]-2-cyclooctylacetate

20




7.68 g (23 mmol) of the compound from Example XXIII and

4.4 g (23 mmol) of cyclooctyl bromide are dissolved in 100 ml of dimethylformamide. 3.36 g (30 mmol) of potassium tertiary butoxide, dissolved in 30 ml of DMF, are added dropwise to this mixture at 0 - 10°C with stirring.

5 The mixture is subsequently stirred at room temperature for a further two hours and then treated with 30 ml of 1N hydrochloric acid. The solvent is then evaporated in vacuo, the residue is taken up in 200 ml of dichloromethane and the dichloromethane solution is washed twice 10 with 100 ml of water. After drying with sodium sulphate, it is concentrated to a small volume in vacuo and the residue is separated by column chromatography (silica gel 60, eluent: toluene/ethyl acetate = 4:1).
Yield: 5.8 g (56.4 % of theory) of yellow oil





15 The compounds shown in Table 1 are prepared in analogy to the procedures of Examples 1 and 2:

Table 1

Ex. No.	R ¹	R ²	R ³	m.p. (°C)	Yield (% of theory)
3	F		CH ₃	95	40.9
4	F		CH ₃	85	53.4
5	Cl		CH ₃	oil	43.4
6	Cl		CH ₃	oil	30.8
7	Cl		CH ₃	oil	67
8	Br		CH ₃	108-110	28.8

2061538

Continuation of Table 1

Ex. No.	R ¹	R ²	R ³	m.p. (°C)	Yield (% of theory)
9	Br		CH ₃	19.2	
10	Br		CH ₃	oil	48
11	OCH ₃		CH ₃	oil	23.3
12	OCH ₃		CH ₃	oil	43.5
13	OCH ₃		CH ₃	oil	39.6
14			CH ₃	oil	82.2

Continuation of Table 1


Ex. No.	R ¹	R ²	R ³	m.p. (°C)	Yield (% of theory)
15			CH ₃	oil	28.9
16			CH ₃	oil	60.8
17			CH ₃	oil	30.5
18			CH ₃	oil	61.8
19			CH ₃	oil	50.4
20			CH ₃	oil	75.6

Continuation of Table 1

Ex. No.	R ¹	R ²	R ³	m.p. (°C)	Yield (% of theory)
21			CH ₃	oil	35.0
22			CH ₃	oil	86.7
23			CH ₃	oil	81.7
24			CH ₃	127	71.9
25	N ₃		CH ₃	102-104	77
26	-NO ₂		CH ₃	91-93	71.4


Example 27

2-[3-Fluoro-4-(quinolin-2-yl-methoxy)phenyl]-2-cyclopentylacetic acid



5 In analogy to the procedure of Example XV, the title compound is prepared from 2.5 g (0.00635 mol) of the compound from Example 1 and 9.35 ml of 1 molar sodium hydroxide solution (0.00935 mol)
 Yield: 1.9 g (78.8 % of theory) of colourless crystals
 10 M.p.: 143 - 145°C

The compounds shown in Table 2 were prepared in analogy to the procedure of Example 27:

Table 2

Ex. No.	R ¹	R ²	m.p. (°C)	Yield (% of theory)
28	F		188-190	62.1
29	F		145	90.1
30	Cl		195	94.4
31	Cl		175	97.7
32	Cl		158-160	95.5
33	Br		108-110	92.1

2061538

Continuation of Table 2

Ex. No.	R ¹	R ²	m.p. (°C)	Yield (% of theory)
34	Br		165	58.9
35	Br		177	74.9
36	OCH ₃		197	66.6
37	OCH ₃		197-199	72.4
38	OCH ₃		174	80.0
39	OCH ₃		167	94.2

Continuation of Table 2


Ex. No.	R ¹	R ²	m.p. (°C)	Yield (% of theory)
40			165	96.3
41			170	99.5
42			133	98.6
43			153	90.3
44			136	89.9
45			161	95.4
46			133	97.2

Continuation of Table 2

Ex. No.	R ¹	R ²	m.p. (°C)	Yield (% of theory)
47			136	92.2
48			159	94.1
49			129	97.1
50			120	85.6
51			210	85.7
52	N ₃		76-79	65

Example 53

{2-[3-Fluoro-(4-quinolin-2-yl-methoxy)phenyl]-2-cycloheptylacetyl}-methanesulphonamide



5 In analogy to the procedure of Example XVI, the title compound is prepared from 1.7 g (0.0042 mol) of the compound from Example 29, 0.4 g (0.042 mol) of dried methanesulphonamide, 0.81 g (0.0042 mol) of N-ethyl-N'-dimethylaminopropylcarbodiimide hydrochloride and 0.51 g (0.0042 mol) of dimethylaminopyridine.

10

The compounds shown in Table 3 are prepared in analogy to the procedure of Example 53:







Table 3


Ex. No.	R ¹	R ²	R ³	m.p. (°C)	Yield (% of theory)
54	F		-NH-SO ₂ -CH ₂ -C ₆ H ₅	105	83.3
55	Cl		-NH-SO ₂ -CH ₂ -C ₆ H ₅	184	66.4
56	Cl		-NH-SO ₂ -CH ₃	80	66
57	Cl		-NH-SO ₂ -CH ₂ -C ₆ H ₅	188	77
58	Br		-NH-SO ₂ -CH ₃	189	63.2
59	OCH ₃		-NH-SO ₂ -CH ₃	130	79.7

Continuation of table 3

Ex. No.	R ¹	R ²	R ³	m.p. (°C)	Yield (% of theory)
60	OCH ₃		-NH-SO ₂ -CH ₃	123	59.7
61	OCH ₃		-NH-SO ₂ -CH(CH ₃) ₂	103	80.8
62			-NH-SO ₂ -CH ₃	196-198	77
63			-NH-SO ₂ -CH ₃	157	56.4
64			-NH-SO ₂ -CH ₃	143	74.7
65			-NH-SO ₂ -CH ₃	147	70.7
66			-NH-SO ₂ -CH ₃	97	79.5
67	N ₁		-NH-SO ₂ -((CH ₂) ₃ -p-J)	63-67	11

The compounds shown in Table 4 were prepared in analogy to the procedure of Example 27:


Table 4



Ex. No.	R ¹	R ²	m.p. (°C)	Yield (% of theory)
5 68			112	92.7
69				(-)-Enantiomer
70				(+)-Enantiomer
71			123	75.1
72			115 (decomposition)	
73			foam	47.9

The compounds shown in Table 5 were prepared in analogy to the procedure of Example 53:


Table 5:



Ex. No.	R ¹	R ²	R ³	m.p. (°C)	Yield (% of theory)
5					
74			-NH-SO ₂ -CH ₃	140	58,0
75			-NH-SO ₂ -CH ₃	amorphous	27
76			-NH-SO ₂ -	189	89,2
77			-NH-SO ₂ -	amorphous	95
78			-NH-SO ₂ -CH ₃	amorphous	92,3

The compounds shown in Table 6 were prepared in analogy to the procedure of Example 2:


Table 6:



5	Ex.No.	R ¹	R ²	R ³	m.p. (°C)	Yield (% of theory)
	79			-CH ₃	oil	95.2

Patent Claims

1. 2-Substituted quinolines of the general formula



in which

5 A, B, D, E, G and L are identical or different and represent hydrogen, hydroxyl, halogen, cyano, carboxyl, nitro, trifluoromethyl, trifluoromethoxy or

10 represent straight-chain or branched alkyl or alkoxy each having up to 8 carbon atoms, or represent aryl having 6 to 10 carbon atoms, which is optionally substituted by halogen, hydroxyl, nitro or cyano,

15 R¹ represents halogen, cyano, nitro, azido, trifluoromethyl, trifluoromethoxy or trifluoromethylthio, or

20 represents straight-chain or branched alkoxy or acyl each having up to 8 carbon atoms, or represents straight-chain or branched alkyl having up to 8 carbon atoms, which is

5

optionally substituted by hydroxyl or alkoxy having up to 6 carbon atoms, or represents aryl having 6 to 10 carbon atoms, or represents straight-chain or branched alkenyl having up to 6 carbon atoms, or represents a group of the formula $-NR^4R^5$,

in which

10

R^4 and R^5 are identical or different and denote hydrogen, straight-chain or branched alkyl having up to 8 carbon atoms, phenyl, acetyl or benzoyl, or represents a saturated or unsaturated, optionally substituted 5- or 6-membered heterocycle having up to 3 hetero atoms from the series comprising sulphur, oxygen and nitrogen,

15

R^2 represents cycloalkyl or -alkenyl having 3 to 12 carbon atoms,

20

R^3 represents a radical of the formula $-OR^6$ or $-NR^7-SO_2-R^6$,

in which

R^6 denotes hydrogen, straight-chain or branched alkyl having up to 8 carbon atoms, or phenyl,

R⁷ denotes hydrogen or straight-chain or branched alkyl having up to 6 carbon atoms,

5 R⁸ denotes aryl having 6 to 10 carbon atoms, which is optionally mono- or disubstituted by identical or different substituents from the series comprising halogen, cyano, hydroxyl, nitro, trifluoromethyl, trifluoromethoxy, trifluoromethylthio, or by straight-chain or branched alkyl or alkoxy each having up to 8 carbon atoms, or denotes straight-chain or branched alkyl having up to 8 carbon atoms, which is optionally substituted by phenyl, which in turn can be substituted by halogen, cyano, nitro, trifluoromethyl, trifluoromethoxy, trifluoromethylthio or hydroxyl, or by straight-chain or branched alkyl or alkoxy each having up to 6 carbon atoms

10

15

20 and their physiologically acceptable salts.

2. 2-Substituted quinolines according to Claim 1,
in which

25 A, B, D, E, G and L are identical or different and represent hydrogen, hydroxyl, fluorine, chlorine, bromine, carboxyl, nitro, trifluoro-

10 R¹ represents fluorine, chlorine, bromine, iodine, cyano, nitro, azido, trifluoromethyl, trifluoromethoxy, or
 represents straight-chain or branched alkoxy or acyl each having up to 6 carbon atoms, or
 represents straight-chain or branched alkyl having up to 6 carbon atoms, which is optionally substituted by hydroxyl or alkoxy having up to 4 carbon atoms, or
 represents straight-chain or branched alkenyl having up to 4 carbon atoms, or
 represents a group of the formula -NR⁴R⁵, in which

20 R^4 and R^5 are identical or different and denote hydrogen or straight-chain or branched alkyl having up to 4 carbon atoms.

R³ represents a radical of the formula -OR⁶ or -NR⁷-SO₂-R⁸,

in which

5 R⁶ denotes hydrogen or straight-chain or branched alkyl having up to 6 carbon atoms,

R⁷ denotes hydrogen or straight-chain or branched alkyl having up to 4 carbon atoms,

10 R⁸ denotes phenyl which is optionally substituted by fluorine, chlorine, bromine, iodine, cyano or by straight-chain or branched alkyl or alkoxy each having up to 6 carbon atoms, or

15 denotes straight-chain or branched alkyl having up to 6 carbon atoms, which is optionally substituted by phenyl which can in turn be substituted by fluorine, chlorine, bromine or trifluoromethyl or by

20 straight-chain or branched alkyl or alkoxy each having up to 4 carbon atoms

and their physiologically acceptable salts.

3. 2-Substituted quinolines according to Claim 1,

in which

5 A, B, D, E, G and L are identical or different and represent hydrogen, hydroxyl, fluorine, chlorine, bromine or straight-chain or branched alkyl having up to 4 carbon atoms,

10 R¹ represents fluorine, chlorine, bromine, nitro, azido or trifluoromethoxy, or represents straight-chain or branched alkoxy or acyl each having up to 4 carbon atoms, or represents straight-chain or branched alkyl having up to 4 carbon atoms, which is optionally substituted by hydroxyl or methoxy, or represents straight-chain or branched alkenyl having up to 4 carbon atoms, or represents a group of the formula -NR⁴R⁵,

in which

20 R⁴ and R⁵ are identical or different and denote hydrogen or straight-chain or branched alkyl having up to 3 carbon atoms, or represents pyrryl, furyl or phenyl,

R² represents cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl,

R^3 represents a radical of the formula $-OR^6$ or $-NR^7-SO_2-R^8$,

in which

5 R^6 denotes hydrogen or straight-chain or branched alkyl having up to 4 carbon atoms,


10 R^7 denotes hydrogen, methyl or ethyl,

15 R^8 denotes phenyl which is optionally substituted by methyl, fluorine, chlorine, bromine, iodine, methoxy or trifluoromethyl, or denotes straight-chain or branched alkyl having up to 4 carbon atoms, which is optionally substituted by phenyl which can in turn be substituted by fluorine, chlorine, bromine, methyl or methoxy

and their physiologically acceptable salts.


4. A compound according to claim 1 wherein such compound is 2-[3-isobutyl-4-(quinoline-2-yl-methoxy)phenyl]-2-cyclopentyl-acetic acid of the formula

20



or a physiologically acceptable salt thereof.

5. A compound according to claim 1 wherein such compound is (2-[3-propyl-4-(quinoline-2-yl-methoxy)phenyl]-2-cycloheptyl-acetic acid) methan sulfonamide of the formula




or a physiologically acceptable salt thereof.

5

6. A compound according to claim 1 wherein such compound is (2-[3-isobutyl-4-(quinoline-2-yl-methoxy)phenyl]-2-cyclopentyl-acetic acid) methan sulfonamide of the formula


10

15




or a physiologically acceptable salt thereof.

7. A compound according to claim 1 wherein such compound is 2-[3-isobutyl-4-(quinoline-2-yl-methoxy)phenyl]-2-cycloheptyl-acetic acid of the formula




or a physiologically acceptable salt thereof.

8. A compound according to claim 1 wherein such compound is (2-[3-isobutyl-4-(quinoline-2-yl-methoxy)phenyl]-2-cycloheptyl-acetic acid) methan sulfonamide of the formula



or a physiologically acceptable salt thereof.

9. A compound according to claim 1, wherein such compound is represented by the formula:




[in which:

R¹ is F, Cl, Br, OCH₃, -N₃, -NO₂, -OCH₃ or -OH, and
 R² is cyclopentyl, cyclohexyl, cycloheptyl or cyclo-octyl,

or a physiologically acceptable salt thereof.

10. A compound according to claim 1, wherein such compound is represented by the formula:



[in which


R¹ is F, Cl, Br, OCH₃, -N₃, -NO₂, -OCH₃ or -OH, and

2061538

23189-7312

R^2 is cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl},
or a physiologically acceptable salt thereof.

11. A compound according to claim 1, wherein such compound is represented by the formula:



[in which:


or a physiologically acceptable salt thereof

12. A pharmaceutical composition for the treatment of diseases of respiratory tract, which comprises an effective amount of the compound or salt as defined in any one of claims 1 to 11 in admixture with a pharmaceutically acceptable auxiliary or excipient.

13. A process for producing the 2-substituted quinoline of the formula (I) as defined in claim 1, which comprises:

[A] when R^3 represents the group $-OR^6$,

[A₁] (i) eliminating the protective group W from a compound of the formula:




[wherein R^1 and R^2 have the meanings given in claim 1,

W is a hydroxyl protective group, and

R^6' has the meaning given for R^6 in claim 1 except for hydrogen],

(iii) etherifying the resulting compound with a 2-halogenomethylquinoline of the formula:




[wherein A, B, D, E, G and L have the meanings given in claim 1, and

Y is halogen]


in a reaction inert solvent, and (iii) where required, hydrolyzing the etherification product to obtain a compound (I) in which R^3 is OR^6 and R^6 is hydrogen, or

[A₂] (i) eliminating the protective group W from a compound of the formula:



[wherein R^1 , $R^{6'}$ and W have the meanings given above],

(ii) etherifying the resulting compound with a 2-halogenomethylquinoline of the formula (III) defined above in a reaction inert solvent to obtain a compound of the formula:



[wherein the symbols have the meanings of the starting materials],

(iii) alkylating the compound of the formula (IVb) with a compound of the formula:



[wherein R^2 has the meanings given in claim 1, and


Z is chlorine, bromine or iodine]

in a reaction inert solvent, and (iv) where required, hydrolyzing the alkylation product to obtain a compound (I) in which R^3 is OR^6 and R^6 is hydrogen, and

[B] when R^3 represents the group $-NR^7-SO_2-R^8$, amidating a compound of the formula (I) obtained above with a sulfonamide of the formula:

2061538

23189-7312



(VI)

{wherein R^7 and R^8 have the meanings given in claim 1}.

14. A process according to claim 13, which further comprises:

separating a mixture of enantiomers of a compound of the formula (I) in which R^3 is OR^6 and R^6 is hydrogen into each enantiomer.

FETHERSTONHAUGH & CO.
OTTAWA, CANADA

PATENT AGENTS

SUBSTITUTE
REEMPLACEMENT

SECTION is not Present

Cette Section est Absente